Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
custirsen + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Sonus Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Custirsen + paclitaxel + carboplatin is an investigational combination therapy studied primarily in advanced or metastatic cancers, including non-small cell lung cancer (NSCLC). Custirsen is an antisense oligonucleotide that inhibits the production of clusterin, a stress-associated chaperone protein that protects cancer cells from apoptosis and contributes to treatment resistance. By reducing clusterin levels, custirsen aims to sensitize tumor cells to chemotherapy. Paclitaxel and carboplatin are established chemotherapeutic agents; paclitaxel stabilizes microtubules and inhibits cell division, while carboplatin induces DNA crosslinking leading to apoptosis. The combination has been evaluated in early-phase clinical trials for its safety profile and potential efficacy in solid tumors[3][5][6][7][8].
- Other names
- custirsen sodium
02
Targets
CLU (Clusterin)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on custirsen + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on custirsen + paclitaxel + carboplatin.